Allergan Pharmaceuticals International

Part of AbbVie

Company

Allergan Pharmaceuticals International develops one asset, in phase 1, no development reported (EDIT‐101 in Leber congenital amaurosis 10). Mostly gene editing acting on CEP290.

1
Asset
Furthest stage
Phase 1, no development reported
0
Trials
0
Signals

Pipeline

1
  • EDIT‐101

    CRISPR gene editing removes a pathogenic intronic sequence in CEP290 to restore normal splicing in retinal photoreceptors.

    Phase 1, no development reported, Gene editing, CEP290, Leber congenital amaurosis 10, eye disorders congenital, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence